Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial

GLP-1

GLP-1, short for glucagon-like peptide-1, is a naturally occurring hormone that plays a key role in regulating blood sugar levels and appetite. It is the target of a class of drugs used to treat type 2 diabetes and obesity, including popular medications from major pharmaceutical companies. GLP-1 therapies have gained significant attention for their effectiveness in weight management and metabolic health, impacting both healthcare practices and pharmaceutical industry trends.

US Employer Healthcare Costs Could Top $19,000 Per Worker in 2027 as Aon Warns of 9.5% Surge
US Employer Healthcare Costs Could Top $19,000 Per Worker in 2027 as Aon Warns of 9.5% Surge
Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients
Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients
Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investment'
Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investment'
Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients
Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients
Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investment'
Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investment'
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
QUICK SPARK: GLP-1 Isn't Just About Weight Loss Anymore—REX's New ETF Proves It
QUICK SPARK: GLP-1 Isn't Just About Weight Loss Anymore—REX's New ETF Proves It

GLP-1 Recent News

Why Hims & Hers Health Are Falling Monday
Why Hims & Hers Health Are Falling Monday
Hims & Hers Health report Q1 results, missing revenue estimates but increasing subscribers. Stock drops more than 9% in after-hours trading.
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing Sites
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing Sites
Eli Lilly plans to invest $4.5 billion in Indiana, expanding its U.S. manufacturing footprint and supporting new weight-loss treatments.
GLP-1 Boom Sparks Potential 'Bubble Effect,' Shrinking Competition In Big Pharma, Warns Deloitte: 'The Question Is...'
GLP-1 Boom Sparks Potential 'Bubble Effect,' Shrinking Competition In Big Pharma, Warns Deloitte: 'The Question Is...'
Deloitte says pharma momentum drives investment interest, but rising competition is limiting growth opportunities in sector.
Novo Nordisk Tumbles in 'Worst Case Scenario': Next-Gen Weight Loss Drug Underperforms
Novo Nordisk Tumbles in 'Worst Case Scenario': Next-Gen Weight Loss Drug Underperforms
Novo Nordisk stock, once the darling of the pharmaceutical world, tumbled as investors reacted to a "worst-case scenario." 
Hims & Hers Under Fire, Stock Tanks on Federal Crackdown, Patent War
Hims & Hers Under Fire, Stock Tanks on Federal Crackdown, Patent War
Hims & Hers stock tanks as the company faces federal intervention, criminal investigation and a patent war.
Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record
Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record
Novo Nordisk's oral weight-loss pill, Wegovy, has seen a record-breaking surge - 3 reasons why the number could be much more.
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback
When Mega-cap tech fades, pharma takes spotlight: LLY and NVO are top picks for long-term growth with strong demand for GLP-1 treatments.
Why Novo Nordisk Stock Keeps Getting Punished For Headlines That Don't Matter
Why Novo Nordisk Stock Keeps Getting Punished For Headlines That Don't Matter
Novo Nordisk is undervalued and oversold, despite strong fundamentals and a promising pipeline. The market's reaction to headlines.
Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032
Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032
Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused short-term volatility but...
Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal
Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal
Novo Nordisk A/S (NYSE:NVO) is showing promising signs of recovery with weight-loss pills, heart-healthy benefits, and bullish analyst reports, following a similar path to UnitedHealth Group Inc's (NYSE:UNH) rebound. Clinical wins, upgrades, and a more forgiving valuation could result in a potential rebound for NVO stock.
Ozempic Is The New Botox And Big Pharma Is Printing Billions
Ozempic Is The New Botox And Big Pharma Is Printing Billions
Ozempic and Zepbound have helped Novo Nordisk and Eli Lilly achieve a combined market cap topping $900 billion.
Eli Lilly Stock Jumps On Weight-Loss Pill Trial
Eli Lilly Stock Jumps On Weight-Loss Pill Trial
Eli Lilly stock dropped more than 20% due to underwhelming results from its drug trials. However, a rebound may be underway.
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.
McDonald's Just Got Hammered By Weight-Loss Drugs — Twice
McDonald's Just Got Hammered By Weight-Loss Drugs — Twice
McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned.
Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan
Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan
Teladoc Health is integrating LillyDirect into its Chronic Care Weight Management program, potentially boosting enrollments.
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli Lilly And Co's (NYSE:LLY) weight-loss and diabetes drugs from its shortage list.
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved